COVID-19 Review Volume 12, Issue 24 pp 26263—26278
Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19
- 1 Vascular Medicine Department, CHU Rennes, French National Health and Medical Research (Inserm), Clinical Investigation Center (CIC) 1414, University of Rennes 1, Rennes F-35033, France
- 2 NuMeCan Institute, Exogenous and Endogenous Stress and Pathological Responses in Hepato-Gastrointestinal Diseases (EXPRES) Team, French National Health and Medical Research (Inserm) U1241, University of Rennes 1, Rennes F-35033, France
- 3 Cellular and Molecular Biology Consultant, Rennes F-35033, France
- 4 University of Reunion Island, INSERM, UMR 1188 Reunion, Indian Ocean Diabetic Atherothrombosis Therapies (DéTROI), CHU de La Réunion, Saint-Denis de La Réunion F-97400, France
- 5 AP-HP Hôpital Avicenne, Oncologie Médicale, Bobigny F-93000, France
- 6 Sorbonne University Paris Nord, INSERM, U942, Cardiovascular Markers in Stressed Conditions, MASCOT, Bobigny F-93000, France
- 7 Department of Pathology, Paris Diderot University, Sorbonne Paris Cité, Paris F-75010, France
Received: October 29, 2020 Accepted: December 10, 2020 Published: December 27, 2020https://doi.org/10.18632/aging.202422
How to Cite
Copyright: © 2020 Omarjee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Inflammaging constitutes the common factor for comorbidities predisposing to severe COVID-19. Inflammaging leads to T-cell senescence, and immunosenescence is linked to autoimmune manifestations in COVID-19. As in SLE, metabolic dysregulation occurs in T-cells. Targeting this T-cell dysfunction opens the field for new therapeutic strategies to prevent severe COVID-19. Immunometabolism-mediated approaches such as rapamycin, metformin and dimethyl fumarate, may optimize COVID-19 treatment of the elderly and patients at risk for severe disease.